Risk factors
EyePoint (EYPT) risk factors
Item 1A of every EyePoint, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors61 risks3 new9 dropped18 reworded
EyePoint disclosed an agreement in principle to settle a DOJ investigation regarding DEXYCU marketing for $4.7 million plus interest. Competition from better-funded rivals threatens DURAVYU and other commercial products. Manufacturing for YUTIQ remains concentrated in Watertown, Massachusetts.
Filed Mar 05, 2026 - FY2024 10-K risk factors67 risks
Capital needs and operating losses dominate the risk section, driven by heavy R&D for the lead product candidate DURAVYU. Regulatory scrutiny, compliance with healthcare laws, and potential patent challenges pose significant threats.
Filed Mar 06, 2025